Altrafin AG’s Danaher DHR Stock Holding History

Altrafin AG’s Portfolio DHR Stock Details DHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,271	Closed	-$638K	–	63
2023 Q3	$638K	Hold	3,271	–	–	0.28%	52
2023 Q2	$696K	Hold	3,271	–	–	0.31%	49
2023 Q1	$731K	Hold	3,271	–	–	0.36%	50
2022 Q4	$770K	Hold	3,271	–	–	0.45%	50
2022 Q3	$749K	Hold	3,271	–	–	0.45%	49
2022 Q2	$735K	Hold	3,271	–	–	0.4%	52
2022 Q1	$851K	Hold	3,271	–	–	0.33%	61
2021 Q4	$954K	Buy	+3,271	New	+$901K	0.34%	61

Other funds holding DHR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Altrafin AG's DHR Position: Q4 2023 in Review

Altrafin AG sold out of Danaher (DHR) in Q4 2023, closing a stake of 3,271 shares — an estimated $638K sold.

Altrafin AG first reported a position in DHR in Q4 2021 and held it in 8 quarters. The position peaked at $954K in Q4 2021. 2,127 funds tracked by Wall St. Rank hold DHR as of Q4 2023.

Altrafin AG reported no remaining Danaher position as of Q4 2023 after selling out during the quarter.
Altrafin AG sold 3,271 Danaher shares in Q4 2023, an estimated $638K.
Altrafin AG first reported a position in Danaher in Q4 2021 and held it in 8 quarters.
Altrafin AG's Danaher position peaked at $954K in Q4 2021.
2,127 funds tracked by Wall St. Rank held Danaher as of Q4 2023.

Based on Altrafin AG's 13F filing for Q4 2023, filed 17 Feb 2026.